CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 256,408	$ 124,482
Short-term investments	414,490	249,964
Contracts receivable	12,645	522
Inventories	7,385	6,121
Investment in Regulus Therapeutics Inc.	65,004	33,622
Other current assets	7,372	8,727
Total current assets	763,304	423,438
Property, plant and equipment, net	87,273	91,084
Licenses, net	5,048	6,579
Patents, net	20,810	18,646
Deposits and other assets	5,481	5,939
Total assets	881,916	545,686
Current liabilities:
Accounts payable	8,781	10,239
Accrued compensation	6,653	7,878
Accrued liabilities	22,283	15,401
Accrued income taxes	4,935
Current portion of long-term obligations	4,649	4,879
Current portion of deferred contract revenue	55,977	35,925
Total current liabilities	103,278	74,322
Long-term deferred contract revenue	151,006	66,656
2 3/4 percent convertible senior notes	148,705	143,990
Long-term obligations, less current portion	6,384	7,402
Long-term financing liability for leased facility	71,097	70,550
Total liabilities	480,470	362,920
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 115,998,221 and 101,481,134 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	116	102
Additional paid-in capital	1,315,643	1,077,150
Accumulated other comprehensive income	29,021	12,480
Accumulated deficit	(943,334)	(906,966)
Total stockholders' equity	401,446	182,766
Total liabilities and stockholders' equity	$ 881,916	$ 545,686